Research map: Optimal timing of letermovir prophylaxis after allogeneic hematopoietic stem cell transplantation: insights from a real-world time-varying exposure analysis

Back to the article

Papers in this map

  1. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation · Francisco M. Marty · 2017 · 1248 citations · Cited by this paper
  2. Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT · Ryszard Swoboda · 2026 · 1 citation · Related
  3. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation · Danniel Zamora · 2021 · 171 citations · Cited by this paper
  4. Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols · 2026 · Related
  5. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study · Roy F. Chemaly · 2020 · 118 citations · Cited by this paper
  6. Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities · 2026 · Related
  7. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial · Domenico Russo · 2023 · 115 citations · Cited by this paper
  8. Institutional risk management for out-of-specification commercial CAR-T products · 2026 · Related
  9. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experience · Andrew P. Lin · 2019 · 87 citations · Cited by this paper
  10. The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P973–P983) · 2026 · Related
  11. Clinical “real‐world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients · Anthony D. Anderson · 2020 · 69 citations · Cited by this paper
  12. Vaccination in haematopoietic stem cell transplantation and cellular therapies: consensus, divergence, and uncertainties in global practice · 2026 · Related
  13. Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation · Lauren D. Stern · 2018 · 66 citations · Cited by this paper
  14. CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy · 2026 · Related
  15. Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients · Luxiang Wang · 2025 · 14 citations · Cited by this paper
  16. The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards · 2026 · Related
  17. An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant · Genovefa A. Papanicolaou · 2025 · 8 citations · Cited by this paper
  18. Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis · 2026 · Related
  19. EASIX and sC5b-9 for early identification of adults at high risk of developing TA-TMA after allo-HCT · 2026 · Related

Source: OpenAlex (CC0)